Severity factors of epistaxis: A retrospective study of 60 cases.
Tunisian Journal of Emergency Medicine · 30.09.2025 · 3 (3)
DOI: 10.66759/9tn3tb34 ↗Kurz gefasst
Fachartikel in der Zeitschrift Tunisian Journal of Emergency Medicine, online erschienen am 30.09.2025. Verfasst von Amal Samet und 4 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).
Abstract (Originalsprache)
Objective
Studying the severity factors of epistaxis.
Methods
Retrospective study involving patients hospitalized in the emergency department and ENT (Ear, Nose, and Throat) department for epistaxis over a period of 5 years (2018-2022). Based on the recommendations of the French Society of Otorhinolaryngology in 2015, we considered epistaxis severe when there was a sudden blood loss leading to acute anemia or signs of hypovolemic shock.
Results
Our study included 60 patients. Epistaxis was considered severe in 12 patients (20%). We found that female sex, black race, and patients with heart failure are severity factors for epistaxis.
Conclusion
Epistaxis is a common condition often considered benign, but in some cases, it can be serious. It is essential for clinicians to recognize forms that are initially or subsequently severe and to initiate optimal management to improve prognosis.
Zitieren
APA
Samet, A., Maalej, F., Mlik, Z., Nbaya, M. A., & Rejab, I. (2025). Severity factors of epistaxis: A retrospective study of 60 cases. Tunisian Journal of Emergency Medicine, 3(3). https://doi.org/10.66759/9tn3tb34
Vancouver
Samet A, Maalej F, Mlik Z, Nbaya MA, Rejab I. Severity factors of epistaxis: A retrospective study of 60 cases. Tunisian Journal of Emergency Medicine. 2025;3(3). doi:10.66759/9tn3tb34
BibTeX
@article{Samet2025,
author = {Samet, Amal and Maalej, Firas and Mlik, Zeineb and Nbaya, Mohamed Ali and Rejab, Imen},
title = {Severity factors of epistaxis: A retrospective study of 60 cases},
journal = {Tunisian Journal of Emergency Medicine},
year = {2025},
volume = {3},
number = {3},
doi = {10.66759/9tn3tb34}
}
EUVIMED